These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 32314931)

  • 1. Diagnostic Accuracy of MCM5 for the Detection of Recurrence in Nonmuscle Invasive Bladder Cancer Followup: A Blinded, Prospective Cohort, Multicenter European Study.
    Roupret M; Gontero P; McCracken SRC; Dudderidge T; Stockley J; Kennedy A; Rodriguez O; Sieverink C; Vanié F; Allasia M; Witjes JA; Colombel M; Sylvester R; Longo F; Montanari E; Palou J
    J Urol; 2020 Oct; 204(4):685-690. PubMed ID: 32314931
    [TBL] [Abstract][Full Text] [Related]  

  • 2. MCM5 urine expression (ADXBLADDER) is a reliable biomarker of high-risk non- muscle-invasive bladder cancer recurrence: A prospective matched case-control study.
    Białek Ł; Czerwińska K; Fus Ł; Krajewski W; Sadowska A; Radziszewski P; Dobruch J; Kryst P; Poletajew S
    Cancer Biomark; 2021; 30(2):139-143. PubMed ID: 32924986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of the performances of the ADXBLADDER test and urinary cytology in the follow-up of non-muscle-invasive bladder cancer: a blinded prospective multicentric study.
    Gontero P; Montanari E; Roupret M; Longo F; Stockley J; Kennedy A; Rodriguez O; McCracken SRC; Dudderidge T; Sieverink C; Vanié F; Allasia M; Witjes JA; Sylvester R; Colombel M; Palou J
    BJU Int; 2021 Feb; 127(2):198-204. PubMed ID: 32745350
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective study.
    Anastasi E; Maggi M; Tartaglione S; Angeloni A; Gennarini G; Leoncini PP; Sperduti I; Di Lascio G; De Stefano V; Di Pierro GB; Del Giudice F; Busetto GM; De Berardinis E; Sciarra A
    Diagn Cytopathol; 2020 Nov; 48(11):1034-1040. PubMed ID: 32562513
    [TBL] [Abstract][Full Text] [Related]  

  • 5. FGFR3, TERT and OTX1 as a Urinary Biomarker Combination for Surveillance of Patients with Bladder Cancer in a Large Prospective Multicenter Study.
    Beukers W; van der Keur KA; Kandimalla R; Vergouwe Y; Steyerberg EW; Boormans JL; Jensen JB; Lorente JA; Real FX; Segersten U; Orntoft TF; Malats N; Malmström PU; Dyrskjot L; Zwarthoff EC
    J Urol; 2017 Jun; 197(6):1410-1418. PubMed ID: 28049011
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria-A Prospective Multicentre Performance Evaluation of ADXBLADDER.
    Dudderidge T; Stockley J; Nabi G; Mom J; Umez-Eronini N; Hrouda D; Cresswell J; McCracken SRC
    Eur Urol Oncol; 2020 Feb; 3(1):42-46. PubMed ID: 31307961
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel urinary biomarkers ADXBLADDER and bladder EpiCheck for diagnostics of bladder cancer: A review.
    Wolfs JRE; Hermans TJN; Koldewijn EL; van de Kerkhof D
    Urol Oncol; 2021 Mar; 39(3):161-170. PubMed ID: 33376063
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Reducing the Frequency of Follow-up Cystoscopy in Low-grade pTa Non-muscle-invasive Bladder Cancer Using the ADXBLADDER Biomarker.
    Rouprêt M; Gontero P; McCracken SRC; Dudderidge T; Stockley J; Kennedy A; Rodriguez O; Sieverink C; Vanié F; Allasia M; Witjes JA; Colombel M; Longo F; Montanari E; Palou J; Sylvester RJ
    Eur Urol Focus; 2022 Nov; 8(6):1643-1649. PubMed ID: 35300937
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction and diagnosis of bladder cancer recurrence based on urinary content of hTERT, SENP1, PPP1CA, and MCM5 transcripts.
    Brems-Eskildsen AS; Zieger K; Toldbod H; Holcomb C; Higuchi R; Mansilla F; Munksgaard PP; Borre M; Ørntoft TF; Dyrskjøt L
    BMC Cancer; 2010 Nov; 10():646. PubMed ID: 21106093
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cystoscopy revisited as the gold standard for detecting bladder cancer recurrence: diagnostic review bias in the randomized, prospective CEFUB trial.
    van der Aa MN; Steyerberg EW; Bangma C; van Rhijn BW; Zwarthoff EC; van der Kwast TH
    J Urol; 2010 Jan; 183(1):76-80. PubMed ID: 19913254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bladder cancer diagnosis and identification of clinically significant disease by combined urinary detection of Mcm5 and nuclear matrix protein 22.
    Kelly JD; Dudderidge TJ; Wollenschlaeger A; Okoturo O; Burling K; Tulloch F; Halsall I; Prevost T; Prevost AT; Vasconcelos JC; Robson W; Leung HY; Vasdev N; Pickard RS; Williams GH; Stoeber K
    PLoS One; 2012; 7(7):e40305. PubMed ID: 22792272
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combinations of urinary biomarkers for surveillance of patients with incident nonmuscle invasive bladder cancer: the European FP7 UROMOL project.
    Zuiverloon TC; Beukers W; van der Keur KA; Nieuweboer AJ; Reinert T; Dyrskjot L; Orntoft TF; Zwarthoff EC
    J Urol; 2013 May; 189(5):1945-51. PubMed ID: 23201384
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Longitudinal follow-up and performance validation of an mRNA-based urine test (Xpert
    Cowan B; Klein E; Jansz K; Westenfelder K; Bradford T; Peterson C; Scherr D; Karsh LI; Egerdie B; Witjes A; Trainer A; Harris R; Goldfarb B; Flax S; Kroeger R; Boyd B; Liao J; Patel S; Bridge J; Reuter V; Quigley N; Brown S; Zhao S; Satya M; Bates M; Simon IM; Campbell S; Lotan Y
    BJU Int; 2021 Dec; 128(6):713-721. PubMed ID: 33793062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non-muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical Trial.
    Witjes JA; Morote J; Cornel EB; Gakis G; van Valenberg FJP; Lozano F; Sternberg IA; Willemsen E; Hegemann ML; Paitan Y; Leibovitch I
    Eur Urol Oncol; 2018 Sep; 1(4):307-313. PubMed ID: 31100252
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prospective Validation of an mRNA-based Urine Test for Surveillance of Patients with Bladder Cancer.
    Valenberg FJPV; Hiar AM; Wallace E; Bridge JA; Mayne DJ; Beqaj S; Sexton WJ; Lotan Y; Weizer AZ; Jansz GK; Stenzl A; Danella JF; Shepard B; Cline KJ; Williams MB; Montgomery S; David RD; Harris R; Klein EW; Bradford TJ; Wolk FN; Westenfelder KR; Trainer AF; Richardson TA; Egerdie RB; Goldfarb B; Zadra JA; Ge S; Zhao S; Simon IM; Campbell SA; Rhees B; Bates MP; Higuchi RG; Witjes JA
    Eur Urol; 2019 May; 75(5):853-860. PubMed ID: 30553612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prospective Validation of Clinical Usefulness of a Novel mRNA-based Urine Test (Xpert® Bladder Cancer Monitor) for surveillance in Non Muscle Invasive Bladder Cancer.
    Elsawy AA; Awadalla A; Elsayed A; Abdullateef M; Abol-Enein H
    Urol Oncol; 2021 Jan; 39(1):77.e9-77.e16. PubMed ID: 32800441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of genito-urinary tract cancer by detection of minichromosome maintenance 5 protein in urine sediments.
    Stoeber K; Swinn R; Prevost AT; de Clive-Lowe P; Halsall I; Dilworth SM; Marr J; Turner WH; Bullock N; Doble A; Hales CN; Williams GH
    J Natl Cancer Inst; 2002 Jul; 94(14):1071-9. PubMed ID: 12122098
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Replacing cystoscopy by urine markers in the follow-up of patients with low-risk non-muscle-invasive bladder cancer?-An International Bladder Cancer Network project.
    Schmitz-Dräger C; Bonberg N; Pesch B; Todenhöfer T; Sahin S; Behrens T; Brüning T; Schmitz-Dräger BJ
    Urol Oncol; 2016 Oct; 34(10):452-9. PubMed ID: 27381893
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Diagnostic performance of minichromosome maintenance 5 (MCM5) in bladder cancer: A systematic review and meta-analysis.
    Sharma G; Sharma A; Krishna M; Ahluwalia P; Gautam G
    Urol Oncol; 2022 Jun; 40(6):235-242. PubMed ID: 35414492
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Predicting Nonmuscle Invasive Bladder Cancer Recurrence and Progression in a United States Population.
    Ravvaz K; Walz ME; Weissert JA; Downs TM
    J Urol; 2017 Oct; 198(4):824-831. PubMed ID: 28433642
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.